Eli Lilly (LLY) announced positive results from the Phase 3 MonarchE and ATTAIN-2 trials, signaling significant advancements ...

The bear case for Eli Lilly has now played out following the reaction to the drugmaker’s oral obesity drug trial, an analyst ...

At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...

Eli Lilly stock dropped more than 20% due to underwhelming results from its drug trials. However, a rebound may be underway.

Eli Lilly's orforglipron outshines Novo Nordisk's oral semaglutide with efficacy & scalability, promising growth in the ...

Shares of Eli Lilly (LLY) are testing a resistance level. If they can break through this resistance, a large more higher may follow.

Eli Lilly (LLY) announced positive results from the Phase 3 MonarchE trial, demonstrating Verzenio's effectiveness in treating early breast cancer, which has reinforced confidence in the company's ...

BRITS scrambling to get hold of the fat jab Mounjaro before a huge price hike have triggered a nationwide freeze on orders.

In 2018, Apple became the first publicly traded company to reach a $1 trillion market capitalization. Several more have ...

The pharmacy said it had also seen more people ordering rival weight-loss drug Wegovy, which is a cheaper alternative.

The drug's US manufacturer has asked UK distributors to stop taking orders from pharmacies until next month's price increase.

Cipla shares are in demand on Dalal Street amid market buzz that it is in talks with Eli Lilly for the Semaglutide drug.